FIS Short Interest Climbs 17% in a Month as Stock Recovers
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Fidelity National Information Services has seen short interest build steadily over the past month even as the stock itself staged a sharp recovery, a divergence that sets up an unusual tension heading into this week's Q3 results.
Short sellers added to positions through October at a pace that stands out. Short interest reached 19.5 million shares by November 3, up 17% over the past 30 days and now equal to 3.8% of the free float. The build was not steady: positions peaked near 20.3 million shares in mid-to-late October before trimming slightly into the week, leaving the weekly change essentially flat at minus 0.15%. The month-long direction is nonetheless clear, shorts were rebuilding even as the stock climbed from roughly $32 to nearly $39.
The borrow market itself offers no particular support for a squeeze narrative. Availability is extremely loose, with more than 6,800% of shares currently short still available to borrow, the lending pool is nowhere near stressed. Borrowing costs have held near 0.38%, essentially unchanged on the week and barely above where they were a month ago. For context, that places the cost firmly in the low-fee category for a stock of this profile. Options positioning eased slightly from last week's elevated levels: the put/call ratio dropped to 0.68 from 0.71 at the end of October, though it still runs above its 20-day average of 0.61, keeping a mild defensive tilt in the market.
The Street spent October cutting targets almost universally, yet few changed their ratings. Goldman Sachs trimmed from $52 to $44 but kept its Buy. Citigroup and Barclays both lowered targets, to $39 and $38 respectively, while holding neutral-equivalent ratings. Truist and Susquehanna both sit at $37. The consensus mean target is $47, against a current price of $38.99, implying around 21% upside on paper, though that figure reflects targets set before this week's print. The EV/EBITDA multiple has contracted about 2% over the past 30 days to 5.4x, while the price-to-book ratio has expanded, up 0.16 points over the same period as the stock recovered. The analyst recommendation divergence factor scores in the 92nd percentile, meaning the gap between bull and bear cases is wider than almost any other name in the universe.
One institutional angle worth noting: Capital Research and Management added more than 20 million shares in the period ending September 30, lifting its reported stake to roughly 7.6% of shares. Fuller and Thaler added over 8 million shares in the same window, bringing its holding to 2.2% of shares. Dodge and Cox remains the largest reported holder at 9.5%, unchanged from prior filings. All 13D/G positions are as last disclosed and may not reflect current levels. On the insider side, the only open-market purchase in the past 90 days was a director buying roughly $58,000 worth of stock in mid-October under a pre-arranged 10b5-1 plan, a scheduled purchase rather than a discretionary signal.
The last earnings print, in August, saw the stock fall 4.3% on the day and 4.5% over the following five days. The question after a 20% one-month rally is whether the Q3 numbers and the fourth-quarter margin guidance, where management projected around 150 basis points of adjusted EBITDA expansion year-on-year, are enough to hold the recovery at current levels.
Stocks in this article
See the live data behind this article on ORTEX.
Open FIS on ORTEX →How this article was generated
- Generated
- 4 Nov 2026, 19:25
- Data as of
- 4 Nov 2026, 19:24
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesIndex RebalancePrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.